Institutional Identity
SRILS is a novel R&D institution dedicated to building a world-class innovation center for biomacromolecules and functions. Driven by a dual-engine strategy of "Basic Research + Translation," we focus on cutting-edge research in cell fate regulation, plant and animal development, immune engineering, and targeted biomolecular technologies.
Strategic Objectives
Original Core
Conduct "0 to 1" basic research to achieve theoretical breakthroughs.
Collaboration
Unite research teams in Shanghai to foster interdisciplinary synergy.
Translation
Build high-originality research hubs while solidifying translation pathways.
Industrial Impact
Drive innovation in medicine and agriculture through basic research breakthroughs.
Ecosystem Growth
Generate radiation effects to promote a culture of scientific innovation.
Board & Management
Scientific Committee
Duke University
Tongji Univ / CAS
Univ. of Chicago
Westlake University
Westlake University
SIOC, CAS
Former Global Head of R&D, Sanofi
Development Milestones
Official Launch
SRILS officially launched construction in Zhangjiang, Shanghai.
Blueprint Approved
The Shanghai Municipal Government formally approved the institute's establishment plan.
Site Selection
Settled in the Zhangjiang Core Area, planning a 6,000 sqm modern laboratory.
Detailed Framework
Refined the implementation path for the "Basic Research + Translation" dual-engine strategy.
Conceptual Origin
A team of top-tier scientists proposed the vision for a novel interdisciplinary R&D institution.
Organizational Innovation
We build a multidimensional innovation system centered on the Board and Executive Committee.
Executive Group
Fudan Univ.
SJTU
Tongji Univ.
ShanghaiTech
Shanghai Pharma
Governance & Autonomy
We implement a Director-Responsibility System under the Board of Directors, fostering scientific vitality through PI-led governance and academic autonomy.
A non-profit institution with significant administrative autonomy and independent financial management.